**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/513, A61P 31/18 — A2

(11) International Publication Number: **WO 00/43014**

(43) International Publication Date: 27 July 2000 (27.07.00)

(21) International Application Number: PCT/US00/01738

(22) International Filing Date: 21 January 2000 (21.01.00)

(30) Priority Data:
60/116,773 22 January 1999 (22.01.99) US

(71) Applicant *(for all designated States except US)*: EMORY UNIVERSITY [US/US]; 1380 S. Oxford Road, Atlanta, GA 30322 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SCHINAZI, Raymond, F. [US/US]; 1524 Regency Walk Drive, Decatur, GA 30033 (US). HAMMOND, Jennifer [US/US]; 407 Taylor Street, Pittsburgh, PA 15224 (US). MELLORS, John, W. [US/US]; 201 Beech Street, Pittsburgh, PA 15218 (US). LIOTTA, Dennis, C. [US/US]; 251 Montrose Drive, McDonough, GA 30253 (US).

(74) Agent: KNOWLES, Sherry, M.; King & Spalding, 191 Peachtree Street, Atlanta, GA 30303-1763 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*Without international search report and to be republished upon receipt of that report.*



*G00001*

(54) Title: HIV-1 MUTATIONS SELECTED FOR BY β-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE

(57) Abstract

The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using β-D-D4FC as "salvage therapy" to patients which exhibit drug resistance to other anti-HIV agents. β-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.



*162162*